2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial-Reference-Cited by-同舟云学术

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Published:2013-09 Issue:9897 Volume:382 Page:1021-1028
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Goldhirsch Aron,Gelber Richard D,Piccart-Gebhart Martine J,de Azambuja Evandro,Procter Marion,Suter Thomas M,Jackisch Christian,Cameron David,Weber Harald A,Heinzmann Dominik,Lago Lissandra Dal,McFadden Eleanor,Dowsett Mitch,Untch Michael,Gianni Luca,Bell Richard,Köhne Claus-Henning,Vindevoghel Anita,Andersson Michael,Brunt A Murray,Otero-Reyes Douglas,Song Santai,Smith Ian,Leyland-Jones Brian,Baselga Jose

Publisher

Elsevier BV

Subject

General Medicine

Reference15 articles.

1. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

2. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

3. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

4. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial;Smith;Lancet,2007

5. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial;Gianni;Lancet Oncol,2011

Cited by 433 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer and Heart Failure: Dangerous Liaisons;Journal of Cardiovascular Development and Disease;2024-08-27

2. HER-2 Receptor and αvβ3 Integrin Dual-Ligand Surface-Functionalized Liposome for Metastatic Breast Cancer Therapy;Pharmaceutics;2024-08-27

3. Frequency of and sex differences in cancer treatment-related cardiac dysfunction in trastuzumab-treated patients with salivary gland cancer: a retrospective cohort study;Cardio-Oncology;2024-07-17

4. HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation?;Cancers;2024-03-11

5. The Relationship of Ribosomal Protein L10 (RPL10) and L41 (RPL41) with Breast Cancer Molecular Subtypes;UHOD-ULUSLAR HEMATOL;2024